Abstract 4645: Plasma cytokine and angiogenic factor (CAF) profiling for identification of markers associated with clinical benefit from bevacizumab (BEV) and with primary tumor presence in a phase II presurgical study of metastatic renal cell carcinoma (mRCC) patients

2013 ◽  
Author(s):  
Alper Yetil ◽  
Eric Jonasch ◽  
Xuemei Wang ◽  
Christopher Wood ◽  
Surena Matin ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Phase Ii ◽  
Metastatic Renal Cell Carcinoma ◽  
Clinical Benefit ◽  
Primary Tumor ◽  
Renal Cell ◽  
Angiogenic Factor ◽  
Plasma Cytokine

Phase II Trial of Low Dose γ -Interferon in Metastatic Renal Cell Carcinoma

1994 ◽  
Vol 152 (3) ◽  
pp. 841-845 ◽  
Author(s):  
Julie A. Ellerhorst ◽  
Robert G. Kilbourn ◽  
Robert J. Amato ◽  
Alexander A. Zukiwski ◽  
Elaine Jones ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Phase Ii ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Low Dose ◽  
Phase Ii Trial ◽  
Γ Interferon

An early phase II trial of S-1 in Japanese patients with cytokine-refractory metastatic renal cell carcinoma

2010 ◽  
Vol 66 (6) ◽  
pp. 1065-1070 ◽  
Author(s):  
Seiji Naito ◽  
Taiji Tsukamoto ◽  
Michiyuki Usami ◽  
Hiroyuki Fujimoto ◽  
Hideyuki Akaza
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Phase Ii ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Early Phase ◽  
Phase Ii Trial ◽  
Japanese Patients

A Phase II Study of Bevacizumab and Everolimus as Treatment for Refractory Metastatic Renal Cell Carcinoma

2013 ◽  
Vol 11 (2) ◽  
pp. 100-106 ◽  
Author(s):  
Lauren C. Harshman ◽  
Sarah Barbeau ◽  
Alex McMillian ◽  
Sandy Srinivas
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Phase Ii ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Phase Ii Study
Sign in / Sign up

Export Citation Format

Share Document